Mount Sinai Department of Psychiatry | Strategic Alliance Partners

Fathers share their heartbreaking stories of loss and advocate for a new model of suicide prevention that emphasizes early intervention and awareness at the 2025 APA Annual Meeting.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Rejoyn, a new app being prescribed as a depression treatment, is an emotional face memory task designed to correct abnormal neural circuits.

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Dennis S. Charney, MD, discussed the discovery of ketamine as a rapid-acting treatment for depression, its journey from skepticism to FDA approval, and its impact on mental health care.

René S. Kahn, MD, PhD, discussed the potential artificial intelligence has to advance the field of psychiatry when diagnosing patients and allowing clinicians to focus on the clinical conversation.

Dennis S. Charney, MD, shared how he encouraged front line health care workers at Mount Sinai during the COVID-19 Pandemic.

The PREDiCTOR study is trying to develop objective measurements for psychiatric diagnoses.

Dennis S. Charney, MD, shared how he has fostered success during his tenure as the Dean of the Icahn School of Medicine at Mount Sinai.

"Our findings provide a mechanistic explanation for the well-known variations in individual responses to drugs and suggest that subjective beliefs could be a direct target for the treatment of substance use disorders," said Xiaosi Gu, PhD, senior author of the study.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

A new study from Mount Sinai Health System and IBM Research is investigating the use of AI in developing objective measures for psychiatric diagnoses.

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.